Cargando…

Two Consecutive Episodes of Severe Delayed Hemolytic Transfusion Reaction in a Sickle Cell Disease Patient

Patients with sickle cell disease (SCD) suffer from anemia and painful vaso-occlusive crisis (VOC) and sometimes need blood transfusions. Delayed hemolytic transfusion reaction (DHTR) is a rare life-threatening complication observed in SCD and mimics VOC. We describe a female SCD patient undergoing...

Descripción completa

Detalles Bibliográficos
Autores principales: Mpinganzima, Clarisse, Haaland, Alf, Holm, Anne Guro Vreim, Thein, Swee Lay, Tjønnfjord, Geir Erland, Iversen, Per Ole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180413/
https://www.ncbi.nlm.nih.gov/pubmed/32351743
http://dx.doi.org/10.1155/2020/2765012
_version_ 1783525813447032832
author Mpinganzima, Clarisse
Haaland, Alf
Holm, Anne Guro Vreim
Thein, Swee Lay
Tjønnfjord, Geir Erland
Iversen, Per Ole
author_facet Mpinganzima, Clarisse
Haaland, Alf
Holm, Anne Guro Vreim
Thein, Swee Lay
Tjønnfjord, Geir Erland
Iversen, Per Ole
author_sort Mpinganzima, Clarisse
collection PubMed
description Patients with sickle cell disease (SCD) suffer from anemia and painful vaso-occlusive crisis (VOC) and sometimes need blood transfusions. Delayed hemolytic transfusion reaction (DHTR) is a rare life-threatening complication observed in SCD and mimics VOC. We describe a female SCD patient undergoing three surgical procedures during which DHTR developed following the first two. Prior to a planned tonsillectomy, she received transfusion and three days after surgery developed severe hemolysis as well as pain and respiratory symptoms. On suspicion of VOC, she received additional transfusions and became hemodynamically unstable, and her hemolytic anemia worsened. Gradually, she recovered and could be discharged after two weeks; DHTR was not suspected. Sixteen months later, an arthroplasty was performed due to avascular necrosis, and again she was transfused preoperatively. Similar to the initial surgery, she developed symptoms and signs of VOC after three days, but this time, DHTR was suspected and further transfusions were withheld. Although immunosuppressive medication did not alleviate the condition, she improved on combined treatment with darbepoietin, rituximab, and eculizumab. Six months later, a second arthroplasty was performed uneventfully after prophylaxis with rituximab and without transfusion. DHTR should be considered in the presence of severe, unexplained hemolysis following a recent transfusion, and additional transfusions in this setting should be given only on vital indication.
format Online
Article
Text
id pubmed-7180413
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-71804132020-04-29 Two Consecutive Episodes of Severe Delayed Hemolytic Transfusion Reaction in a Sickle Cell Disease Patient Mpinganzima, Clarisse Haaland, Alf Holm, Anne Guro Vreim Thein, Swee Lay Tjønnfjord, Geir Erland Iversen, Per Ole Case Rep Hematol Case Report Patients with sickle cell disease (SCD) suffer from anemia and painful vaso-occlusive crisis (VOC) and sometimes need blood transfusions. Delayed hemolytic transfusion reaction (DHTR) is a rare life-threatening complication observed in SCD and mimics VOC. We describe a female SCD patient undergoing three surgical procedures during which DHTR developed following the first two. Prior to a planned tonsillectomy, she received transfusion and three days after surgery developed severe hemolysis as well as pain and respiratory symptoms. On suspicion of VOC, she received additional transfusions and became hemodynamically unstable, and her hemolytic anemia worsened. Gradually, she recovered and could be discharged after two weeks; DHTR was not suspected. Sixteen months later, an arthroplasty was performed due to avascular necrosis, and again she was transfused preoperatively. Similar to the initial surgery, she developed symptoms and signs of VOC after three days, but this time, DHTR was suspected and further transfusions were withheld. Although immunosuppressive medication did not alleviate the condition, she improved on combined treatment with darbepoietin, rituximab, and eculizumab. Six months later, a second arthroplasty was performed uneventfully after prophylaxis with rituximab and without transfusion. DHTR should be considered in the presence of severe, unexplained hemolysis following a recent transfusion, and additional transfusions in this setting should be given only on vital indication. Hindawi 2020-04-14 /pmc/articles/PMC7180413/ /pubmed/32351743 http://dx.doi.org/10.1155/2020/2765012 Text en Copyright © 2020 Clarisse Mpinganzima et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Mpinganzima, Clarisse
Haaland, Alf
Holm, Anne Guro Vreim
Thein, Swee Lay
Tjønnfjord, Geir Erland
Iversen, Per Ole
Two Consecutive Episodes of Severe Delayed Hemolytic Transfusion Reaction in a Sickle Cell Disease Patient
title Two Consecutive Episodes of Severe Delayed Hemolytic Transfusion Reaction in a Sickle Cell Disease Patient
title_full Two Consecutive Episodes of Severe Delayed Hemolytic Transfusion Reaction in a Sickle Cell Disease Patient
title_fullStr Two Consecutive Episodes of Severe Delayed Hemolytic Transfusion Reaction in a Sickle Cell Disease Patient
title_full_unstemmed Two Consecutive Episodes of Severe Delayed Hemolytic Transfusion Reaction in a Sickle Cell Disease Patient
title_short Two Consecutive Episodes of Severe Delayed Hemolytic Transfusion Reaction in a Sickle Cell Disease Patient
title_sort two consecutive episodes of severe delayed hemolytic transfusion reaction in a sickle cell disease patient
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180413/
https://www.ncbi.nlm.nih.gov/pubmed/32351743
http://dx.doi.org/10.1155/2020/2765012
work_keys_str_mv AT mpinganzimaclarisse twoconsecutiveepisodesofseveredelayedhemolytictransfusionreactioninasicklecelldiseasepatient
AT haalandalf twoconsecutiveepisodesofseveredelayedhemolytictransfusionreactioninasicklecelldiseasepatient
AT holmannegurovreim twoconsecutiveepisodesofseveredelayedhemolytictransfusionreactioninasicklecelldiseasepatient
AT theinsweelay twoconsecutiveepisodesofseveredelayedhemolytictransfusionreactioninasicklecelldiseasepatient
AT tjønnfjordgeirerland twoconsecutiveepisodesofseveredelayedhemolytictransfusionreactioninasicklecelldiseasepatient
AT iversenperole twoconsecutiveepisodesofseveredelayedhemolytictransfusionreactioninasicklecelldiseasepatient